Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma скачать в хорошем качестве

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma

Dr Georgina Long speaks to ecancer about phase 3 KEYNOTE-716 study investigating distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma. Initially, she talks about the background and the methodology of the study. Dr Long then discusses the results. The results showed adjuvant pembrolizumab vs placebo for resected stage IIB and IIC melanoma significantly improved DMFS, with continued reduction in the risk of recurrence, and a favourable benefit-risk profile. In the study, the safety profile of pembrolizumab was consistent with previously reported studies in patients with solid tumours, and no new safety signals were observed at the time of DMFS analysis. Treatment-related adverse events Grade 3 or higher were observed in 17% of patients receiving pembrolizumab versus 5% of patients receiving placebo. Immune-mediated events and infusion reactions were higher with pembrolizumab. She concludes by discussing the future impact of these results can be on the treatment of melanoma.